Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement

Executive Summary

• The TSX Venture Exchange granted Rakovina Therapeutics a 30‑day extension to close its non‑brokered private placement, now expected to complete on or before April 9, 2026.
• The offering seeks to raise up to $1,000,000 by selling 8,333,334 common shares at $0.12 per share.
• Net proceeds will be used for near‑term working capital and strategic initiatives while the company evaluates longer‑term financing options.

Key Details

• Extension Granted: 30‑day extension; new anticipated closing date ≤ April 9, 2026 (or other acceptable dates).
• Offering Size: Up to 8,333,334 common shares.
• Price per Share: $0.12.
• Gross Proceeds Target: Approximately $1.0 million.
• Finder’s Fee: Company may pay a finder’s fee to eligible finders who introduce subscribers.
• Use of Net Proceeds:
• Provide near‑term working capital.
• Support ongoing corporate activities and strategic initiatives.
• Continue evaluation of longer‑term financing alternatives.

Notable Quotes

(No executive quotes were included in the release.)